Drug updated on 4/16/2024
| Dosage Form | Tablet (oral; sitagliptin/metformin hydrochloride 50 mg/500 mg) Tablet (oral; sitagliptin/metformin hydrochloride 50 mg/1000 mg) |
| Drug Class | Dipeptidyl peptidase-4 inhibitors and biguanides |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Summary
- Sitagliptin and metformin hydrochloride (Janumet) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- One systematic review/meta-analysis document was reviewed, which included a total of 10 randomized controlled trials involving the use of sitagliptin among other drugs for treating type 2 diabetes patients.
- The study population consisted of adult patients diagnosed with type 2 diabetes, however no specific subgroup considerations were mentioned within the studys provided.
- In comparison to active control group treatments such as metformin/dapagliflozin/sitagliptin/glimepiride, gemigliptin showed comparable efficacy in reducing haemoglobin A1c levels at a duration of 24 weeks.
- Gemigliptin demonstrated superior effectiveness over passive controls like placebo/rosuvastatin in achieving HbA1c less than <7% after both twelve and twenty-four weeks respectively; this indicates its potential utility for improving glycemic control among diabetic individuals when compared against these alternatives.
- Adverse events reported during the studies were similar between gemigliptin treatment groups and their respective controls; additionally, there was no increased risk observed for hypoglycaemia amongst those receiving gemigliptin therapy indicating that it may be well-tolerated by most users over six months usage period.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Janumet (sitagliptin and metformin hydrochloride) Prescribing Information. | 2022 | Merck Sharp & Dohme LLC Rahway, NJ, USA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: a meta-analysis. | 2021 | Endocrinology and Metabolism |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. | 2022 | AACE: Endocrine Practice |
| Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. | 2020 | Canadian Journal of Diabetes |
| Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. | 2020 | Diabetology & Metabolic Syndrome |